American Century Companies Inc. increased its position in Puma Biotechnology Inc (NYSE:PBYI) by 63.4% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 44,102 shares of the biopharmaceutical company’s stock after acquiring an additional 17,115 shares during the period. American Century Companies Inc. owned approximately 0.12% of Puma Biotechnology worth $3,855,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in PBYI. Bank of Montreal Can acquired a new stake in shares of Puma Biotechnology in the 1st quarter worth about $195,000. Wells Fargo & Company MN increased its holdings in shares of Puma Biotechnology by 10.0% in the 1st quarter. Wells Fargo & Company MN now owns 24,151 shares of the biopharmaceutical company’s stock worth $899,000 after acquiring an additional 2,201 shares during the period. Canada Pension Plan Investment Board increased its holdings in shares of Puma Biotechnology by 101.9% in the 1st quarter. Canada Pension Plan Investment Board now owns 43,000 shares of the biopharmaceutical company’s stock worth $1,600,000 after acquiring an additional 21,700 shares during the period. Suntrust Banks Inc. increased its holdings in shares of Puma Biotechnology by 98.1% in the 1st quarter. Suntrust Banks Inc. now owns 28,314 shares of the biopharmaceutical company’s stock worth $1,052,000 after acquiring an additional 14,023 shares during the period. Finally, BNP Paribas Arbitrage SA increased its holdings in shares of Puma Biotechnology by 999.1% in the 1st quarter. BNP Paribas Arbitrage SA now owns 23,071 shares of the biopharmaceutical company’s stock worth $858,000 after acquiring an additional 20,972 shares during the period. 80.98% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This report was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright law. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/09/12/american-century-companies-inc-has-3-86-million-position-in-puma-biotechnology-inc-pbyi.html.

A number of analysts recently weighed in on the stock. Stifel Nicolaus reaffirmed a “buy” rating and issued a $110.00 price objective (down previously from $118.00) on shares of Puma Biotechnology in a report on Thursday, August 10th. BidaskClub raised shares of Puma Biotechnology from a “hold” rating to a “buy” rating in a report on Friday. Citigroup Inc. raised shares of Puma Biotechnology to a “buy” rating and set a $105.00 price objective on the stock in a report on Sunday, May 28th. J P Morgan Chase & Co set a $105.00 price objective on shares of Puma Biotechnology and gave the stock a “buy” rating in a report on Wednesday, August 9th. Finally, Credit Suisse Group increased their price objective on shares of Puma Biotechnology from $118.00 to $136.00 and gave the stock an “outperform” rating in a report on Monday. One research analyst has rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $110.70.

In other Puma Biotechnology news, SVP Richard Paul Bryce sold 15,000 shares of the business’s stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $100.09, for a total transaction of $1,501,350.00. Following the completion of the sale, the senior vice president now directly owns 28,239 shares of the company’s stock, valued at approximately $2,826,441.51. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Alan H. Auerbach sold 13,175 shares of the business’s stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $94.73, for a total value of $1,248,067.75. Following the sale, the insider now directly owns 4,170,623 shares of the company’s stock, valued at $395,083,116.79. The disclosure for this sale can be found here. Insiders sold 35,173 shares of company stock valued at $3,373,689 over the last ninety days. 22.70% of the stock is currently owned by company insiders.

Puma Biotechnology Inc (PBYI) opened at 105.55 on Tuesday. The company’s market cap is $3.93 billion. The company has a 50-day moving average of $88.21 and a 200-day moving average of $64.22. Puma Biotechnology Inc has a 12 month low of $28.35 and a 12 month high of $109.85.

Puma Biotechnology (NYSE:PBYI) last released its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($2.10) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.32) by $0.78. Analysts predict that Puma Biotechnology Inc will post ($8.60) EPS for the current year.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Want to see what other hedge funds are holding PBYI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Puma Biotechnology Inc (NYSE:PBYI).

Institutional Ownership by Quarter for Puma Biotechnology (NYSE:PBYI)

Receive News & Stock Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related stocks with our FREE daily email newsletter.